Copyright
©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1215-1233
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1215
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1215
Ref. | N (all) n (non-survivors) | Age (year) | Male | Pre-existing CLD | Type of liver disease | Elevated LFTs on admission (%) | LFTs levels on admission. ALT/AST/ALP/GGT (U/L)/TB (μmoL) | Selected complications or clinical outcomes |
Cao et al[51]. China | N = 102 (n = 17) | 53 vs 72 | 47.1% vs 76.5% | 2.4% vs 5.9% | - | ALT: NR vs 41.1% | ALT: NR vs 40 | ALI: 24.7% vs 76.5%; ARDS: 5.9% vs 88.2%; Shock: 3.5% vs 41.1%; MV: 2.4% vs 70.6% |
Chen et al[52]. China | N = 274 (n = 113) | 51 vs 68 | 55% vs 73% | - | HBV surface antigen positivity | ALT: 19% vs 27%; AST: 16% vs 52% | ALT: 20 vs 28; AST: 25 vs 45; ALP: 64 vs 76; GGT: 28 vs 42; TB: 8.4 vs 12.6 | ALI: 2% vs 9%; ARDS: 52% vs 100%; Shock: 0% vs 41%; MV: 82% vs 16% |
Chen et al[53]. China | N = 55 (n = 19)1 | 72 vs 77 | 50% vs 84.2% | 2.8% vs 5.3% | - | ALT: 19.4% vs 31.6%; AST: 50% vs 73.7% | ALT: 40 vs 44;AST: 55 vs 78 | MV: 30.6% vs 68.4% |
Du et al[54]. China | N = 852 | 65.8 | 72.9% | 5.9% | - | ALT: 16.5%; AST: 32.9%; TB: 35.3% | ALT: 72.9; AST: 94.4; TB: 18.4 | ALI: 35.3%; ARDS: 74.1%; Shock: 81.2%; MV: 93%3 |
Wu et al[42]. China | N = 84 (n = 44)4 | 50 vs 68.5 | 77.5% vs 65.9% | 3.5%5 | - | - | ALT: 35 vs 39; AST: 38.5 vs 37; TB: 11.6 vs 14.5 | MV: 57.5% vs 97.8%3; Others reported as association |
Yang et al[55]. China | N = 922 | 69.8 | 53.3% | 3.3% | - | - | ALT: 27; AST: 31; TB: 13.6 | ALI: 16.5%; ARDS: 80.2%; MODS: 15.4% |
Yang et al[39]. China | N = 52 (n = 32) | 51.9 vs 64.6 | 70% vs 66% | - | - | - | TB: 13.1 vs 19.5 | ALI: 30% vs 28%; ARDS: 45% vs 81%; MV: 35% vs 94% |
Zhang et al[44]. China | N = 822 | 72.5 | 65.9% | 2.4% | - | ALT: 30.6%; AST: 61.1%; TB: 30.6% | ALT: 26; AST: 72; TB: 13.6 | Hepatic damage: 78%; Liver-associated death: 1.2%; MV: 40.2% |
Zhou et al[43]. China | N = 191 (n = 54) | 52 vs 69 | 59% vs 70% | - | - | ALT: 24% vs 48% | ALT: 27 vs 40 | ARDS: 7% vs 93%; Shock: 0% vs 70%; MV: 2% vs 100%3 |
- Citation: Omar AS, Kaddoura R, Orabi B, Hanoura S. Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. World J Hepatol 2021; 13(10): 1215-1233
- URL: https://www.wjgnet.com/1948-5182/full/v13/i10/1215.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i10.1215